ロード中...
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
Aprepitant, a selective high-affinity antagonist of human substance P/neurokinin 1 (NK(1)) receptors, is the active ingredient of EMEND(®) which has recently been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant undergoes extensive metabolism, pri...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2007
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2673828/ https://ncbi.nlm.nih.gov/pubmed/17722507 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|